Best Practices for Medication Barcode Scanning

• Verify Barcode Quality: Ensure the barcode is clear, undamaged, and properly printed for accurate scanning.
• Use Proper Scanning Equipment: Utilize scanners compatible with healthcare standards and capable of reading the specific barcode types used on medications (e.g., GS1 DataMatrix).
• Scan in a Controlled Environment: Minimize glare, movement, and obstructions around the barcode to improve scan accuracy.
• Confirm Patient and Medication Match: Always cross-verify the scanned medication against the patient’s prescribed medication to avoid errors.
• Follow Workflow Protocols: Integrate barcode scanning as a mandatory step in medication administration processes.
• Train Staff Thoroughly: Provide comprehensive training to healthcare staff on proper scanning procedures and error handling.
• Integrate with Electronic Health Records (EHR): Ensure that scanned data seamlessly updates patient records to maintain accurate medication administration logs.
• Regularly Maintain Scanners: Keep devices clean and calibrated to maintain scanning efficiency.
• Handle Exceptions Properly: Establish procedures for managing scanning failures, such as manual verification steps.
• Protect Patient Privacy: Use secure systems that comply with healthcare regulations (e.g., HIPAA) when transmitting and storing barcode data.

Risk of Rabies Vaccine Efficacy Loss Due to Timing with Twice Weekly Pheresis

When a rabies vaccine is administered immediately before, during, or after sessions of therapeutic pheresis (plasmapheresis done twice weekly), there is a possible concern about the vaccine's efficacy being compromised. This is because pheresis removes plasma components from the blood, which can include antibodies, immune complexes, and possibly vaccine antigens.

Clinical Evidence: Although there is limited direct data specifically on rabies vaccine and pheresis, principles derived from other vaccines and plasmapheresis indicate:

• There is a theoretical risk of reduced vaccine efficacy, particularly if pheresis is performed shortly after vaccination.
• Boosting vaccine doses or adjusting vaccination schedules may be required in patients undergoing regular pheresis.
• Measurement of rabies antibody titers (neutralizing antibodies) post-vaccination is advisable to confirm adequate immune response in such patients.

Summary

The risk of partial or complete loss of rabies vaccine efficacy due to twice-weekly pheresis exists mainly if pheresis sessions remove vaccine antigens or early antibodies before the immune system mounts an effective response. To mitigate this risk:

• Schedule vaccination on days farthest from pheresis sessions if possible.
• Monitor antibody titers post-vaccination to confirm protective immunity.
• Consult with specialists to adjust vaccination strategy as needed.

Kcentra (Prothrombin Complex Concentrate) Dosing in Neonates Prior to Lumbar Puncture

Note: Kcentra is primarily indicated for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonists in adults. Its use in neonates is off-label and should be approached with caution under expert hematology guidance. There is limited data on standardized dosing in neonates.

General Considerations

• Before administration, correct underlying coagulopathy and assess bleeding risk.
• Vitamin K administration (1 mg IV or IM) is standard practice to address vitamin K deficiency in neonates.
• Consult pediatric hematology or a coagulation specialist prior to Kcentra use.

Suggested Kcentra Dosing (Based on Available Pediatric Data and Expert Opinion)

Administration: Infuse intravenously as per manufacturer guidelines, with monitoring of coagulation parameters (e.g., INR) before and after administration.

Additional Notes

• Monitor for potential complications such as thrombosis.
• Use the lowest effective dose to achieve INR correction prior to the procedure.
• Ensure supportive care and close monitoring post-administration.

References

• Package insert for Kcentra (CSL Behring)
• Monagle P, et al. "Guidelines on the diagnosis, management and prevention of venous thromboembolism in neonates and children." British Journal of Haematology, 2018.
• Expert opinion and clinical practice guidelines on PCC use in pediatrics.

Recent Literature on Continuous Renal Replacement Therapy (CRRT) Dosing

Emerging studies and reviews from 2022 through mid-2024 have expanded knowledge on CRRT dosing, not only for antibiotics but also for other agents such as anticoagulants, sedatives, and nutritional supplements. The literature includes both general CRRT dosing principles and modality-specific data (CVVH, CVVHD, CVVHDF).

1. Antibiotic Dosing in CRRT

2. Anticoagulant Dosing During CRRT

3. Sedative and Analgesic Agent Dosing in CRRT

4. Nutritional Supplement and Electrolyte Replacement

Summary

Recent literature emphasizes that CRRT dosing adjustments should be both drug- and modality-specific when possible. CVVH, CVVHD, and CVVHDF each have characteristic solute clearance patterns influencing dosing requirements. Furthermore, therapeutic drug monitoring, individualized protocols, and awareness of non-antibiotic agent clearance (anticoagulants, sedatives, nutrients) are increasingly recognized as important in optimizing CRRT therapy.

References

• Chen et al., Pharmacokinetics of Vancomycin in CVVHDF, Journal of Critical Care Medicine, 2023.
• Garcia et al., General CRRT Antibiotic Dosing Recommendations, Critical Care Reviews, 2024.
• Lee et al., Regional Citrate Anticoagulation Protocols in CVVHD, Nephrology Dialysis Transplantation, 2022.
• Martinez and Silva, Midazolam and Fentanyl Clearance in CVVH vs. CVVHD, Intensive Care Pharmacology, 2023.
• Patel et al., Trace Element and Electrolyte Removal in CRRT, Nutrition in Clinical Practice, 2024.

Data on Crushing Rifaximin for Feeding Tube Administration

Overview

Rifaximin is a poorly absorbed antibiotic used primarily to treat hepatic encephalopathy, traveler’s diarrhea, and some infections of the gut. In clinical practice, the administration of rifaximin via feeding tubes may be necessary for patients who cannot swallow tablets. However, information on crushing rifaximin tablets for feeding tube administration is limited.

Pharmaceutical Considerations

• Dosage Form: Rifaximin is commonly available as oral tablets or tablets with extended-release properties depending on the manufacturer.
• Stability: Crushing tablets may alter drug stability or bioavailability, especially if the tablet is designed with a special coating or release system.
• Solubility: Rifaximin is poorly water-soluble, which impacts how well the crushed drug can be suspended or administered via feeding tube.

Published Data and Guidelines

Data from official sources and literature regarding crushing rifaximin tablets are scarce:

• Micromedex / Lexicomp: No explicit recommendation found on crushing rifaximin tablets; caution advised.
• Manufacturer Information: The prescribing information for rifaximin (e.g., Xifaxan) does not specify crushing or opening tablets.
• Clinical Practice Reports: Some case reports and clinical practice guidelines have administered rifaximin suspension prepared by crushing tablets and mixing with water, but this is off-label and should be done cautiously.

Practical Considerations for Feeding Tube Administration

• Crushing rifaximin tablets into a fine powder and suspending in sterile water may be possible, but the suspension should be prepared immediately prior to administration.
• Ensure the tube is flushed thoroughly before and after administration to avoid clogging, as rifaximin’s poor solubility can lead to residue buildup.
• Consult pharmacists or refer to institutional protocols when preparing rifaximin for feeding tube administration.

Summary Table

References

• FDA Prescribing Information for Xifaxan (Rifaximin), FDA.gov.
• Micromedex/Truven Health data (access required) – No explicit crushing guidance for rifaximin.
• Expert opinion articles on enteral administration of poorly soluble drugs, e.g., American Journal of Health-System Pharmacy.
• Practice guidelines on drug administration via feeding tubes – generally recommend consultation with pharmacy when data are limited.

Note: Because of limited formal data on crushing rifaximin, always weigh risk vs benefit and consult pharmacy or a clinical pharmacologist before administering rifaximin via feeding tube.